Indaptus Therapeutics, Inc. INDP
3.13 USD -0.16 (-4.86%)
Regular-session close
3.13 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
3.10 Day range 3.31
0.92 52-week range 5.96
- YTD
- +7.56%
- 1 year
- +51.21%
News
benzinga.com Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket Aytu Biopharma surged 42.9% after strong revenue and a proposed Rosemont acquisition; Cloudastructure led gainers, while Bridger Aerospace and Stem fell.benzinga.com Indaptus Therapeutics Q3 EPS $(0.01) Up From $(2.98) YoY Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.01) per share. This is a 99.66 percent increase over losses of $(2.98) per share from the same period last year.
globenewswire.com Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced…
benzinga.com Netflix, Intuitive Surgical, Pegasystems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures mixed; Netflix fell 6% after mixed Q3 results and weaker guidance. Alpha Teknova, Intuitive Surgical and others also declined premarket.
globenewswire.com Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced…
globenewswire.com Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their…
globenewswire.com Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the…
defenseworld.net Comparing Indaptus Therapeutics (NASDAQ:INDP) & Aldeyra Therapeutics (NASDAQ:ALDX) Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast…
defenseworld.net Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) is expected to be issuing its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of…
globenewswire.com Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer…
globenewswire.com Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer…
globenewswire.com Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer…
defenseworld.net Critical Review: Redhill Biopharma (NASDAQ:RDHL) and Indaptus Therapeutics (NASDAQ:INDP) Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare…
globenewswire.com Indaptus Therapeutics Provides Clinical Update Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with…
globenewswire.com Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A.
globenewswire.com Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued…
globenewswire.com Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral…
globenewswire.com Indaptus Therapeutics Announces Reverse Stock Split NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer…
globenewswire.com Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral…
globenewswire.com Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral…
globenewswire.com Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer…
globenewswire.com Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections,…
globenewswire.com Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections,…
